Old Articles: <Older 8501-8510 Newer> |
|
Chemistry World January 14, 2013 Andrew Turley |
Laropiprant recalled Merck & Co has said it is recalling Tredaptive cholesterol tablets in response to trial results that raised safety concerns and the recommendations of a European Medicines Agency safety panel. |
Chemistry World January 11, 2013 Andrew Turley |
Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. |
Chemistry World January 8, 2013 Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
Chemistry World January 8, 2013 Andy Extance |
Phenome center move ends GSK role Running costs have forced the national MRC-NIHR Phenome Centre to move from the Harlow labs of pharmaceutical company GlaxoSmithKline, where it was originally going to be sited. |
Chemistry World January 7, 2013 Laura Howes |
Digging up ancient drug formulations Some of the medicines we take today, such as aspirin, have a long history. But analysis of drugs found in an ancient shipwreck that sank in the second century BC threw up some compounds that are still being used by the medical profession today. |
Chemistry World January 3, 2013 Andrew Turley |
TB drug milestone for bedaquiline Bedaquiline (sirturo) has become the first drug to be approved in the US for the treatment of multi-drug resistant tuberculosis |
Chemistry World January 3, 2013 Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Chemistry World December 20, 2012 Andrew Turley |
Gilead buys YM for $510m US pharma company Gilead is to buy YM BioSciences, a drug discovery firm based in Ontario, Canada, for $510 million. |
Chemistry World December 17, 2012 Jessica Cocker |
Helping the fight against flu Scientists from Australia and the US have developed a synthesis for a drug that gives higher yields and antiviral activity than currently used commercial drugs, such as Relenza (zanamivir) and Tamiflu (oseltamivir), they claim. |
Pharmaceutical Executive December 1, 2012 William Looney |
The Puzzle Master: Dr. Guido Rasi Europe's chief regulator charts a strategy from many moving parts. |
<Older 8501-8510 Newer> Return to current articles. |